



Zurich, Switzerland

## AETNA to be taken over by CVS HEALTH

**Subject:** AETNA to be taken over by CVS HEALTH

**Date:** 27.11.2018

**Effective Date:** 29.11.2018

**Contact:** LIMEYARD Ltd, Customer Support, Phone +41 (0)44 261 04 71, Mail: [info@limeyard.ch](mailto:info@limeyard.ch)

Dear Client,

AETNA to be taken over by CVS HEALTH.

Changes to LIMEYARD USA 500 index:

	Old	No replacement
Effective date	29.11.2018	
Name	AETNA ORD (NYS)	
ISIN	US00817Y1082	
RIC	AET.N	
Bloomberg ticker	AET UN EQUITY	
Shares	327'400'000	
Free Float	100.00 %	
Price	Close of 28.11.2018	
Action	Deletion	

	Old	New
Effective date	29.11.2018	29.11.2018
Name	CVS HEALTH ORD (NYS)	CVS HEALTH ORD (NYS)
ISIN	US1266501006	US1266501006
RIC	CVS.N	CVS.N
Bloomberg ticker	CVS UN EQUITY	CVS UN EQUITY
Shares	1'018'063'785	1'292'359'505
Free Float	100.00%	100.00%
Price	Close of 28.11.2018	Close of 28.11.2018
Action	Share change	Share change

Yours sincerely,  
LIMEYARD Ltd.



## Disclaimer

LIMEYARD is a proprietary and nonproprietary benchmark provider, delivering rule-based, compliant traditional and smart-beta investable solutions to institutions on the sell and buy sides.

This document is provided for internal use only. The information contained herein is proprietary to LIMEYARD and may not be reproduced or disseminated in whole or in part without prior written permission from LIMEYARD. Although the information provided herein is believed to be reliable and has been obtained from sources believed to be reliable, LIMEYARD makes no representation or warranty, expressed or implied, with respect to the fairness, correctness, accuracy, reasonableness, or completeness of such information. The information is subject to change without notice.

This document is for information purposes only and does not constitute investment advice or an offer to sell or the solicitation of an offer to buy any security of any entity or for the services of LIMEYARD. LIMEYARD provides all information as part of a general information service and without regard to investors' particular circumstances. LIMEYARD shall not be liable for any damages arising from any inaccuracy in the information.

This document should not be the basis of an investment decision. An investment decision should be based on customary and thorough due-diligence procedures, which should include, but not be limited to, a thorough review of all relevant offering documents as well as consultation with legal, tax, and regulatory experts.

Exposure to an asset class, a sector, a geography, or a strategy represented by an index can be achieved either through a replication of the list of constituents and the respective weightings of the constituents or through investable instruments based on that index. LIMEYARD does not sponsor, endorse, sell, promote, or manage any investment product that seeks to provide an investment return based on the performance of any index. LIMEYARD makes no assurance that investment products based on the market index used in this document will accurately track the performance of the index itself or return positive performance. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited.